Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.64 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946597 | 0.83 | PRKCQ (0.51) | SRCPRKCQPRKCDEGFRKDR | |
| SCHEMBL4897913 | 0.79 | SRC (1.00) | SRCEGFRFYNMAP2K1ABL1 | |
| SCHEMBL4947549 | 0.78 | PRKCQ (1.00) | SRCPRKCQPRKCDEGFRFLT1 | |
| SCHEMBL3994723 | 0.76 | PRKCQ (0.54) | SRCPRKCQPRKCD | |
| SCHEMBL4944952 | 0.71 | EGFR (0.45) | SRCPRKCQPRKCDEGFR | |
| SCHEMBL4941352 | 0.71 | PRKCQ (0.60) | SRCPRKCQPRKCD | |
| SCHEMBL13266874 | 0.67 | HRH3 (0.74) | CHEK1ACHELRRK2HRH3 | |
| SCHEMBL5520893 | 0.67 | PRKCQ (0.53) | SRCPRKCQPRKCDCHEK1ABL1 | |
| SCHEMBL3995602 | 0.66 | ADORA1 (0.45) | PRKCQ | |
| SCHEMBL4947940 | 0.66 | CSNK1A1 (0.36) | PRKCQPRKCDLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101273047-A | Thieno [2, 3-B ] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH CORP (US) | 2008-09-24 | — | — | CN | disclosed |
| EP-1937690-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
| WO-2007038519-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | SRC 370/4885PRKCQ 286/4885PRKCD 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.